The Food and Drug Administration (FDA) on Wednesday granted accelerated approval to Bayer AG‘s (OTC: BAYRY) Hyrnuo (sevabertinib) for adults with a specific type of advanced lung cancer. The approval ...

Bayer will cover the full cost of the test regardless of the test results, treatment decision and patient’s insurance coverage for up to 500 patients in the U.S. Bayer will not cover the associated ...

Television viewers tuning into the Tournament Of Roses Parade on Jan. 2 can expect to see a float from at least one local company. Bayer Environmental Science, a consumer lawn care product ...

Bayer announced that new data from the company’s advanced radiology portfolio will be presented at the 2023 European Congress of Radiology (ECR), taking place from March 1-5 in Vienna, Austria. The ...

Bayer announced initiation of a phase I clinical trial with 225Ac-GPC3 (BAY 3547926), an investigational targeted alpha radiopharmaceutical being developed to treat tumours expressing Glypican-3 (GPC3 ...

Bayer is giving away 10,000 bottles of the Advanced Aspirin every day for the next 10 days for a total of 100,000 free bottles! With that many free bottles, I bet many of you will be able to get this ...

The Brigham Young University student rocketeers blasted their way into history today, setting a new GUINNESS WORLD RECORDS title for Highest launch of an Alka-Rocket* in the 2018 Bayer Alka-Rocket ...

ECULLY, France--(BUSINESS WIRE)--Just one year after acquiring Bayer Garden and Bayer Advanced consumer businesses, SBM Company has completed another step in its ambitious expansion plans by ...

TRENTON, N.J. (AP) --Bayer is looking for a speedy remedy for stagnant aspirin sales. The company whose name is synonymous with the pain reliever is introducing a reformulated aspirin Monday that ...

Life science giant Bayer is selling a piece of its crop science division, which is a major employer in Research Triangle Park. The German company announced Thursday that it has agreed to sell its ...

Bayer announced today initiation of a Phase I clinical trial with 225Ac-GPC3 (BAY 3547926), an investigational targeted alpha radiopharmaceutical being developed to treat tumors expressing Glypican-3 ...